Columbus, OH

A small trial by investigators at the National Cancer Institute holds promise to bring personalized cell therapy into the solid tumor arena, after more than a decade of success in blood cancers. A new cellular immunotherapy technique that combines features of a well-known personalized therapy used in blood cancers and...

“Personalized” immunotherapy appears effective in small study of patients with metastatic solid tumors

Cancer Health

Early findings from a small clinical trial provide evidence that a new cellular immunotherapy approach may be effective in treating metastatic solid tumors. In the trial, researchers from the National Institutes of Health (NIH) genetically engineered normal white blood cells, known as lymphocytes, from each patient to produce receptors that recognize and attack their specific cancer cells. These initial findings are from people with metastatic colorectal cancer who had already undergone multiple earlier treatments. The personalized immunotherapy tumor and was able to keep the tumors from regrowing for up to seven months. The findings were published July 11, 2024, in Nature Medicine.

Immunotherapy Approach Shows Potential in Some People With Metastatic Solid Tumors

Daniel Rubin, PharmD, discusses key takeaways from a study exploring the use. of a clinical decision tool for biomarker documentation. A study, presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting by Daniel Rubin, PharmD, investigated how a clinical decision support (CDS) tool can improve the documentation of biomarker results in cancer care.

Known Biomarkers, Better Care: Optimizing a CDS Tool to Guide Personalized Cancer Treatment

Mazyar Shadman, MD, MPH, discusses the rationale for combining sonrotoclax plus zanubrutinib for treatment-naive chronic lymphocytic leukemia. Mazyar Shadman, MD, MPH, Innovators Network Endowed Chair, associate professor, Clinical Research Division, Fred Hutchinson Cancer Center; associate professor, Medical Oncology Division, University of Washington School of Medicine, discusses the rationale for comparing the efficacy of sonrotoclax (BGB-11417) plus zanubrutinib (Brukinsa) with standard-of-care venetoclax (Venclexta) plus obinutuzumab (Gazyva) in the phase 3 CELESTIAL-TNCLL trial (NCT06073821) of treatment-naive patients with chronic lymphocytic leukemia (CLL).

Dr Shadman on the Evaluation of Zanbrutinib Plus Sonrotoclax in Treatment-Naive CLL

The drug lorlatinib (Lorbrena) is superior to crizotinib (Xalkori) as an initial treatment for people with advanced non-small-cell lung cancer (NSCLC) that has changes in the ALK gene, according to new results from a global clinical trial. The findings are the latest from the CROWN study. Participants were randomly assigned...

Lorbrena Is Effective as Initial Treatment of ALK-Positive Non-Small-Cell Lung Cancer

Chronic lymphocytic leukemia (CLL) is a type of cancer affecting a type of white blood cell in the blood and bone marrow. It often progresses slowly and is diagnosed most often during routine blood testing. Understanding the stages of CLL—from stage 0 to 4—can help you navigate a CLL diagnosis....

Stages of Chronic Lymphocytic Leukemia (CLL)

COLUMBIA, Mo. — All cancers are difficult to treat, and blood cancers are among the trickiest to handle. However, a common high blood pressure drug is helping to weaken leukemia’s defenses against chemotherapy. Researchers from the University of Missouri School of Medicine are using losartan in a new...

Common high blood pressure drug losartan boosts chemotherapy’s ability to beat leukemia

Community Voices represent independent, third-party users who have joined our contributor program but not yet verified their accounts. Community Voices are expected, like all users, to adhere to our Community Standards.

community_voice

Total Apex Sports & Entertainment

Do your loved ones consult you regularly when they face a crisis? Intelligence is a branch of psychology that lacks a standard definition. Some scientists claim that it is a single ability and others state it comprises aptitudes and skills. Intelligent zodiac signs learn from their experiences and easily recognize and solve problems.

5 Most Intelligent Zodiac Signs

MedwireNews: Researchers have used a machine learning approach to create a panel of eight blood biomarkers that can identify people at risk for developing Parkinson’s disease (PD) up to 7 years before the first signs or symptoms. “Our identified panel of blood biomarkers significantly advances NSD [neuronal synuclein disease]...

Blood test predicts Parkinson’s disease up to 7 years before symptom onset

Despite being the second-most common rheumatic autoimmune disease in the United States, Sjögren’s syndrome remains under-recognized, with patients often waiting 3 years for a proper diagnosis, according to the Sjögren’s Foundation. The disease impacts nearly 4 million Americans — nine out of 10 being women —...

World Sjögren’s Day shines light on a disease that too often goes years without diagnosis

Doctors typically divide small cell lung cancer (SCLC) into limited or extensive stages, depending on whether the cancer is in one lung, both lungs, or has spread to distant areas. Staging for small cell lung cancer (SCLC) can help identify how advanced the cancer is and its best treatment. In...

How does small cell lung cancer staging work?

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have uncovered new details about the role of a protein called interferon regulatory factor (IRF1) in cancer progression and treatment response, offering new insight that can potentially help improve the effectiveness of cancer immunotherapy. The study, published in Cell Reports, reveals...

Study Reveals Dual Role of Protein in Cancer Treatment

Patient enrollment is anticipated to begin in the first quarter of 2025. Jaguar Gene Therapy has been cleared by the FDA to evaluate its JAG201 gene therapy in pediatric patients with autism spectrum disorder (ASD) due to SHANK3 haploinsufficiency and those diagnosed with Phelan-McDermid syndrome.1. “We are pleased to have...

Trial Cleared to Start Dosing Pediatric Patients With Autism Due to SHANK3 Haploinsufficiency

California State

Contributors represent independent, third-party users who have joined our contributor program and self-verified their accounts. They have also demonstrated their experience writing hard news for other outlets. Contributors are expected, like all users, to adhere to our Community Standards.

contributor

The HD Post

CALIFORNIA – Plaintiffs, in a case against Wells Fargo alleging that the bank knowingly took part in a marketing scam, asked the court, July 8, not to grant a motion for summary judgment.

Class action lawsuit says Wells Fargo customers lost over $160 Million

Chicago, IL

Writers represent independent, third-party users who have joined our contributor program and self-verified their accounts. Writers are expected, like all users, to adhere to our Community Standards.

writer

Foodie in Chicago

Shortly before 3 AM, people in the Chicago area may have felt their houses shake as a 3.4-magnitude earthquake occurred about 60 miles west of the city. (CHICAGO) The United States Geological Survey (USGS) reported a 3.4-magnitude earthquake around Somonauk, IL. Somonauk is in DeKalb and LaSalle Counties, 64 miles west of Chicago.

Did You Feel the Earthquake?

New Jersey State

Morristown Minute

A new initiative aims to provide housing for vulnerable Medicaid members, enhancing community wellness and support. MORRIS COUNTY, N.J. - In a significant move to tackle housing instability among Medicaid recipients, New Jersey's Human Services Commissioner Sarah Adelman, along with Community Affairs Commissioner Jacquelyn A. Suárez, today announced the availability of $95 million in funding for developers. This initiative, part of the Healthy Homes program, is designed to create affordable housing opportunities for NJ FamilyCare members who are either homeless, at risk of homelessness, or currently living in institutional settings.

$95 Million for Healthy Homes: Housing for Medicaid Members

AIC100 now has a regenerative medicine advanced therapy designation from the FDA for the treatment of recurrent anaplastic thyroid cancer. The FDA has granted AIC100 regenerative medicine advanced therapy (RMAT) designation for the treatment of recurrent anaplastic thyroid cancer. AIC100 is a chimeric antigen receptor (CAR) T-cell product. RMAT designation...

New CAR T Granted FDA RMAT Designation for Anaplastic Thyroid Cancer

Brain cancer is rare. Some forms are particularly uncommon, including choroid plexus tumors, pineal tumors, and hemangiomas. Brain cancers occur when an atypical group of cells in the brain uncontrollably grow and multiply. There are several different types of brain cancer. Some are extremely rare. This article lists and explains...

Rare brain cancers: What to know

Emily Standley Allard

If you know someone born under the zodiac sign of Cancer, you've probably felt the intensity of their emotions. When a Cancer gets emotional, they can turn a light shower into a monsoon or a friendly hug into a lifetime commitment! Cancer, the fourth sign of the zodiac, spans from June 21 to July 22. Represented by the Crab, Cancer is a Water sign, deeply connected to emotions, intuition, and the subconscious. Governed by the Moon, which represents emotions, Cancer is known for its profound sensitivity, nurturing nature, and emotional depth. Let's delve into the complexities of Cancer and explore why they are considered one of the most emotional and sensitive signs of the zodiac.

The Most Sensitive and Emotional Zodiac Sign

SurvivorNet

Discover new hope for refractory follicular lymphoma with FDA-approved Brukinsa and Gazyva. This groundbreaking treatment offers improved outcomes for patients who have exhausted other options.

Coping with Refractory Follicular Lymphoma: New Treatment On The Horizon

NewsBreak

Entrectinib Shows Durable Responses in ROS1-Positive NSCLC

The tyrosine kinase inhibitor entrectinib shows promising responses in patients with non–small cell lung cancer harboring a ROS1 mutation. Entrectinib (Rozlytrek) delivered durable responses and progression-free...

Entrectinib Shows Durable Responses in ROS1-Positive NSCLC

Comments / 0